Skip to main content

Chronic Myeloproliferative Disorders

5
Pipeline Programs
4
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
4 programs
1
3
American ginsengPhase 31 trial
baclofen/amitriptyline/ketamine gelPhase 31 trial
ondansetronPhase 31 trial
Compound 506U78Phase 11 trial
Active Trials
NCT00004239Terminated10Est. Jan 2002
NCT00719563Completed364Est. Aug 2013
NCT00516503Completed208Est. Jan 2010
+1 more trials
Otsuka
OtsukaJapan - Tokushima
1 program
1
rabbit anti-thymocyte globulinPhase 1/21 trial
Active Trials
NCT00448357Completed54Est. Nov 2015
Knight Therapeutics
Knight TherapeuticsQC - Montréal
5 programs
filgrastimN/A1 trial
microarray analysisN/A1 trial
therapeutic allogeneic lymphocytesPHASE_1_21 trial
anti-thymocyte globulinPHASE_21 trial
imatinib mesylatePHASE_21 trial
Active Trials
NCT00253552Terminated4Est. May 2006
NCT00900055Completed213Est. Aug 2016
NCT00245037Completed147Est. Aug 2015
+2 more trials
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
immunosuppressive therapyN/A1 trial
Active Trials
NCT00813501TerminatedEst. Jun 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alliance PharmaceuticalsAmerican ginseng
Alliance Pharmaceuticalsbaclofen/amitriptyline/ketamine gel
Alliance Pharmaceuticalsondansetron
Knight Therapeuticsanti-thymocyte globulin
Knight Therapeuticsimatinib mesylate
Otsukarabbit anti-thymocyte globulin
Knight Therapeuticstherapeutic allogeneic lymphocytes
Alliance PharmaceuticalsCompound 506U78
City Therapeuticsimmunosuppressive therapy
Knight Therapeuticsfilgrastim
Knight Therapeuticsmicroarray analysis

Clinical Trials (11)

Total enrollment: 1,310 patients across 11 trials

NCT00719563Alliance PharmaceuticalsAmerican ginseng

American Ginseng in Treating Patients With Fatigue Caused by Cancer

Start: Oct 2008Est. completion: Aug 2013364 patients
Phase 3Completed
NCT00516503Alliance Pharmaceuticalsbaclofen/amitriptyline/ketamine gel

Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Start: Feb 2008Est. completion: Jan 2010208 patients
Phase 3Completed
NCT00006348Alliance Pharmaceuticalsondansetron

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

Start: Oct 2000Est. completion: Sep 2001100 patients
Phase 3Completed
NCT00281879Knight Therapeuticsanti-thymocyte globulin

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Start: Feb 2006Est. completion: Mar 2008200 patients
Phase 2Terminated
NCT00245128Knight Therapeuticsimatinib mesylate

Imatinib Mesylate in Treating Patients With Myelofibrosis

Start: Aug 2005Est. completion: Oct 201110 patients
Phase 2Terminated
NCT00448357Otsukarabbit anti-thymocyte globulin

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Start: Oct 2005Est. completion: Nov 201554 patients
Phase 1/2Completed
NCT00245037Knight Therapeuticstherapeutic allogeneic lymphocytes

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Start: Jun 2005Est. completion: Aug 2015147 patients
Phase 1/2Completed
NCT00004239Alliance PharmaceuticalsCompound 506U78

506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

Start: Dec 1999Est. completion: Jan 200210 patients
Phase 1Terminated
NCT00813501City Therapeuticsimmunosuppressive therapy

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

Start: Jun 2008Est. completion: Jun 2010
N/ATerminated
NCT00253552Knight Therapeuticsfilgrastim

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

Start: May 2004Est. completion: May 20064 patients
N/ATerminated
NCT00900055Knight Therapeuticsmicroarray analysis

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

Start: Jun 1975Est. completion: Aug 2016213 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.